CLINICAL TRIALS PROFILE FOR LATANOPROSTENE BUNOD
✉ Email this page to a colleague
All Clinical Trials for Latanoprostene Bunod
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01895972 ↗ | Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT | Completed | Bausch & Lomb Incorporated | Phase 3 | 2013-07-05 | The objective of this study is to demonstrate the clinical safety of latanoprostene bunod 0.024% once daily (QD) over a 1-year treatment period. |
| NCT01895985 ↗ | Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers | Completed | Bausch & Lomb Incorporated | Phase 1 | 2013-07-01 | The objective of this study is to evaluate the effect of latanoprostene bunod dosed once daily (QD) in reducing intraocular pressure (IOP) measured over a 24-hour period in healthy subjects. |
| NCT03931317 ↗ | Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity | Completed | Bausch & Lomb Incorporated | N/A | 2018-12-03 | The purpose of this research study is to compare the effect of Latanoprostene Bunod and Timolol on eye pressure and blood vessels of the back of the eye. |
| NCT03931317 ↗ | Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity | Completed | University of California, San Diego | N/A | 2018-12-03 | The purpose of this research study is to compare the effect of Latanoprostene Bunod and Timolol on eye pressure and blood vessels of the back of the eye. |
| NCT03949244 ↗ | Nailfold Capillary Blood Flow With Latanoprost Bunod | Completed | Icahn School of Medicine at Mount Sinai | Phase 4 | 2019-08-15 | The purpose of this study is to look at the relationship of small blood vessels irregularities observed with an imaging system called video nailfold capillaroscopy in people with primary open-angle glaucoma. Nailfold capillaroscopy (NFC) is a video camera with a magnifying lens used for studying the movement of blood in small blood vessels. It is simple, safe and does not penetrate the skin. The skin fold that is at the tip of the finger is called the "nailfold". NFC has been used to assess blood vessel narrowing in patients with glaucoma. |
| NCT04140279 ↗ | A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension | Recruiting | Bausch & Lomb Incorporated | Phase 4 | 2021-12-01 | The primary objective of this study is to determine the effect of latanoprostene bunod (LBN) ophthalmic solution 0.024% (a single dose and 7 days of once daily [QD] dosing) on 2 aspects of aqueous humor (AqH) dynamics (episcleral venous pressure [EVP] and outflow facility) in participants with ocular hypertension (OHT). |
| NCT04981886 ↗ | Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma | Not yet recruiting | Salus University | Phase 4 | 2021-08-01 | Glaucoma is the second leading cause of blindness and the first leading cause of irreversible vision loss worldwide. The intraocular pressure (IOP) is the only modifiable risk factor for all the spectrum of glaucoma. Reducing IOP in glaucoma increases the likelihood of preventing progression of the disease and preserving the quality of life of the patient. Although prostaglandin analogs (PGAs) and prostamides (PMs) are de facto first-line treatment options for managing glaucoma, it is a common clinical experience to see their treatment effects plateau to a level beyond which no clinically significant IOP reduction is likely. It is also common to find minimal IOP treatment effects in the following conditions: patients with normal tension glaucoma (NTG), patients with thicker central corneal thickness (CCT), and patients with higher levels of corneal hysteresis (CH). CH is a possible proxy for the ability of the scleral tissue around the optic nerve to dissipate energy away from the optic nerve fibers. Netarsudil, a rho-kinase inhibitor was recently approved by the FDA for the treatment of glaucoma and ocular hypertension. There is a paucity of research on the efficacy of netarsudil in patients with NTG, thicker CCT, and higher levels of CH. This study aims to investigate the above issues by evaluating the efficacy of netarsudil and bimatoprost in subjects with NTG, thicker corneas, and higher levels of CH. Hypotheses - Netarsudil will have non-inferior efficacy compared to Bimatoprost in treating NTG. - Corneal thickness and corneal hysteresis will reduce the efficacy of netarsudil similar to bimatoprost in NTG. - Netarsudil will change corneal thickness and corneal hysteresis similar to bimatoprost in NTG. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Latanoprostene Bunod
Condition Name
Clinical Trial Locations for Latanoprostene Bunod
Trials by Country
Clinical Trial Progress for Latanoprostene Bunod
Clinical Trial Phase
Clinical Trial Sponsors for Latanoprostene Bunod
Sponsor Name
